Literature DB >> 18754024

Alterations of NFIA in chronic malignant myeloid diseases.

F Bernard, V Gelsi-Boyer, A Murati, S Giraudier, V Trouplin, J Adélaïde, J Rey, S Olschwang, W Vainchenker, M Chaffanet, N Vey, M J Mozziconacci, D Birnbaum.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18754024     DOI： 10.1038/leu.2008.228

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  MiR-212-3p inhibits cell proliferation and promotes apoptosis by targeting nuclear factor IA in bladder cancer.

Authors:  Xiaoming Wu; Hao Chen; Gaoyue Zhang; Jianhui Wu; Wei Zhu; Yanqin Gu; Y I He
Journal:  J Biosci       Date:  2019-09       Impact factor: 1.826

2.  Nuclear factor IA is expressed in astrocytomas and is associated with improved survival.

Authors:  Hae-Ri Song; Ignacio Gonzalez-Gomez; Greg S Suh; Deborah L Commins; Richard Sposto; Floyd H Gilles; Benjamin Deneen; Anat Erdreich-Epstein
Journal:  Neuro Oncol       Date:  2010-01-25       Impact factor: 12.300

3.  Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model.

Authors:  Nancy A Jenkins; Neal G Copeland; Emilie A Bard-Chapeau; Anh-Tuan Nguyen; Alistair G Rust; Ahmed Sayadi; Philip Lee; Belinda Q Chua; Lee-Sun New; Johann de Jong; Jerrold M Ward; Christopher Ky Chin; Valerie Chew; Han Chong Toh; Jean-Pierre Abastado; Touati Benoukraf; Richie Soong; Frederic A Bard; Adam J Dupuy; Randy L Johnson; George K Radda; Eric Cy Chan; Lodewyk Fa Wessels; David J Adams
Journal:  Nat Genet       Date:  2013-12-08       Impact factor: 38.330

Review 4.  Myeloid malignancies: mutations, models and management.

Authors:  Anne Murati; Mandy Brecqueville; Raynier Devillier; Marie-Joelle Mozziconacci; Véronique Gelsi-Boyer; Daniel Birnbaum
Journal:  BMC Cancer       Date:  2012-07-23       Impact factor: 4.430

5.  Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.

Authors:  Julien Rocquain; Nadine Carbuccia; Virginie Trouplin; Stéphane Raynaud; Anne Murati; Meyer Nezri; Zoulika Tadrist; Sylviane Olschwang; Norbert Vey; Daniel Birnbaum; Véronique Gelsi-Boyer; Marie-Joelle Mozziconacci
Journal:  BMC Cancer       Date:  2010-08-02       Impact factor: 4.638

6.  Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms.

Authors:  K L Rice; X Lin; K Wolniak; B L Ebert; W Berkofsky-Fessler; M Buzzai; Y Sun; C Xi; P Elkin; R Levine; T Golub; D G Gilliland; J D Crispino; J D Licht; W Zhang
Journal:  Blood Cancer J       Date:  2011-11-11       Impact factor: 11.037

7.  Frequent hypermethylation of orphan CpG islands with enhancer activity in cancer.

Authors:  Min Gyun Bae; Jeong Yeon Kim; Jung Kyoon Choi
Journal:  BMC Med Genomics       Date:  2016-08-12       Impact factor: 3.063

8.  High-throughput sequencing identifies an NFIA/CBFA2T3 fusion gene in acute erythroid leukemia with t(1;16)(p31;q24).

Authors:  F Micci; J Thorsen; I Panagopoulos; K B Nyquist; B Zeller; A Tierens; S Heim
Journal:  Leukemia       Date:  2012-09-11       Impact factor: 11.528
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.